• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share
FOR IMMEDIATE RELEASE
August 18, 2017
Contact: HHS Press Office
202-690-6343
media@hhs.gov

Secretary Price Statement on the Signing of the FDA Reauthorization Act of 2017

Health and Human Services Secretary Tom Price, M.D. issued the following statement after President Trump signed the FDA Reauthorization Act of 2017:

“By signing the FDA Reauthorization Act of 2017 into law, President Trump is ensuring that safe and effective, life-saving treatments will continue to reach American patients, from innovative new drugs, to generic drugs, biosimilars, and medical devices. The law will support our team at FDA as they carry out the HHS mission to enhance and protect the health and well-being of the American people and continue to advance medical breakthroughs.”

###
Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.
Like HHS on Facebook Exit disclaimer icon, follow HHS on Twitter @HHSgov Exit disclaimer icon, and sign up for HHS Email Updates.
Last revised: August 18, 2017

Subscribe to RSS

Receive latest updates

Subscribe to our RSS